<div id="readability-page-1"><p><span>CryoPort (NASDAQ:CYRX - Get Free Report)</span> had its price target raised by stock analysts at Needham &amp; Company LLC  from $12.00 to $13.00 in a report released on Wednesday,Benzinga reports. The firm currently has a &#34;buy&#34; rating on the stock. Needham &amp; Company LLC's price target points to a potential upside of 53.12% from the company's current price.</p><p>Other equities research analysts have also issued research reports about the stock. UBS Group raised their target price on shares of CryoPort from $11.00 to $12.50 and gave the stock a &#34;buy&#34; rating in a report on Wednesday, November 5th. Weiss Ratings  reaffirmed a &#34;sell (d+)&#34; rating on shares of CryoPort in a research report on Monday, December 29th. Eight research analysts have rated the stock with a Buy rating, one  has issued  a Hold rating and one  has issued  a Sell rating to the stock. Based on data from MarketBeat, the stock  has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $12.94.</p><p><b>Get Our Latest Report on CYRX</b></p><h2>CryoPort Trading Up 3.4%</h2><p>CryoPort stock opened at $8.49 on Wednesday. CryoPort has a 1 year low of $4.58 and a 1 year high of $11.45. The firm's 50 day moving average price is $9.51 and its 200-day moving average price is $9.41. The company has a debt-to-equity ratio of 0.40, a current ratio of 15.77 and a quick ratio of 15.01. The stock has a market cap of $425.09 million, a P/E ratio of 7.26 and a beta of 1.69. </p><p>CryoPort (NASDAQ:CYRX - Get Free Report) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.08). The firm had revenue of $45.45 million during the quarter, compared to the consensus estimate of $42.92 million. CryoPort had a negative return on equity of 11.07% and a net margin of 35.57%. On average, equities analysts predict that  CryoPort will post -0.99 earnings per share for the current fiscal year. </p><h2>Insider Transactions at CryoPort</h2><p>In related news, Director Ramkumar Mandalam sold 11,570 shares of the stock in a transaction that occurred on Wednesday, December 10th. The stock was sold at an average price of $9.99, for a total value of $115,584.30. Following the completion of the transaction, the director directly owned 80,758 shares in the company, valued at approximately $806,772.42. This represents a 12.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own  10.10% of the company's stock. </p><h2>Institutional Investors Weigh In On CryoPort</h2><p>Several institutional investors and hedge funds have recently modified their holdings of CYRX. Assenagon Asset Management S.A. increased its holdings in  CryoPort by 37.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,498,774 shares of the company's stock worth $14,208,000 after purchasing an additional 408,263 shares during the period.  SG Americas Securities LLC grew its position in shares of  CryoPort by 663.2% during the third quarter. SG Americas Securities LLC now owns 127,280 shares of the company's stock worth $1,207,000 after buying an additional 110,602 shares in the last quarter.  Y Intercept Hong Kong Ltd purchased a new stake in shares of  CryoPort during the second quarter worth approximately $292,000.  Bullseye Asset Management LLC lifted its stake in  CryoPort by 23.0% in the second quarter. Bullseye Asset Management LLC now owns 260,168 shares of the company's stock worth $1,941,000 after acquiring an additional 48,605 shares during the last quarter.  Finally, Thematics Asset Management lifted its stake in  CryoPort by 12.8% in the second quarter. Thematics Asset Management now owns 1,914,885 shares of the company's stock worth $14,285,000 after acquiring an additional 216,937 shares during the last quarter. Hedge funds and other institutional investors own  92.90% of the company's stock. </p><h2>CryoPort Company Profile</h2> (Get Free Report)<p>CryoPort, Inc <span>NASDAQ: CYRX<span></span></span> is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.  </p><p>CryoPort's product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.</p><h2>See Also</h2><ul><li>Five stocks we like better than CryoPort</li><li>New Copper-Rich “Kraken” Zone Discovered</li><li>Elon Warns “America Is Broke”. Trump’s Plan Inside.</li><li>America’s 1776 happening again</li><li>3 Signs You May Want to Switch Financial Advisors</li><li>Silver's squeeze is tightening - opportunity forming</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1lSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1lSWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in CryoPort Right Now?</h2><p>Before you consider CryoPort, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CryoPort wasn't on the list.</p><p>While CryoPort currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CYRX

<p>Needham & Company LLC has raised its price target for CryoPort (NASDAQ:CYRX) from $12.00 to $13.00, maintaining a "buy" rating. This suggests a potential upside of 53.12% from the current price. Other analysts, including UBS Group, have also issued positive ratings. CryoPort's stock opened at $8.49, with a market cap of $425.09 million. The company reported a revenue of $45.45 million but missed EPS estimates. Institutional investors hold 92.90% of the stock, indicating strong interest in the company.</p>

Needham & Company LLC Forecasts Strong Price Appreciation for CryoPort (NASDAQ:CYRX) Stock